Cancer-Testis Antigens and Immunotherapy in the Light of Cancer Complexity

REFERENCES

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9–29. PubMed PMID:24399786.
   PubMed Web of Science ®Google Scholar
• Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science 2011;331(6024):1553–1558. PubMed PMID:21436442.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646–674. PubMed PMID:21376230. Epub 2011/03/08. eng.
   PubMed Web of Science ®Google Scholar
• Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446(7132):153–158. PubMed PMID:17344846.
   PubMed Web of Science ®Google Scholar
• Berraondo P, Umansky V, Melero I. Changing the tumor microenvironment: new strategies for immunotherapy. Cancer Res 2012;72(20):5159–5164. PubMed PMID:22826606. Epub 2012/07/25. eng.
   Google Scholar
• Bolouri H. Network dynamics in the tumor microenvironment. Semin Cancer Biol 2014;30:52–59. PubMed PMID:24582766.
   Google Scholar
• Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013;501(7467):346–354. PubMed PMID:24048067.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Butterfield LH, Tarhini AA, et al. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012;62(5):309–335. PubMed PMID:22576456.
   PubMed Web of Science ®Google Scholar
• Fox BA, Schendel DJ, Butterfield LH, et al. Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011;9(1):214. PubMed PMID:22168571.
   PubMedGoogle Scholar
• Payne KK, Toor AA, Wang XY, Manjili MH. Immunotherapy of cancer: reprogramming tumor-immune crosstalk. Clin Dev Immunol 2012;2012:760965. PubMed PMID:23097673.
   Google Scholar
• Zendman AJ, Ruiter DJ, Van Muijen GN. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 2003;194(3):272–288. PubMed PMID:12548548.
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004;4:1. PubMed PMID:14738373.
   PubMedGoogle Scholar
• Scanlan MJ, Gure AO, Jungbluth AA, et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002;188:22–32. PubMed PMID:12445278.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Pandey A, Saba R, et al. Cancer testis antigens: a novel target in lung cancer. Int Rev Immunol 2012;31(5):321–343. PubMed PMID:23083344.
   PubMed Web of Science ®Google Scholar
• Pandey A, Kurup A, Shrivastava A, et al. Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol 2012;31(5):302–320. PubMed PMID:23083343.
   PubMed Web of Science ®Google Scholar
• Mirandola L, Cannon JM, Cobos E, et al. Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol 2011;30(2–3):127–137. PubMed PMID:21557639.
   PubMed Web of Science ®Google Scholar
• Grizzi F, Franceschini B, Hamrick C, et al. Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med 2007;5:3. PubMed PMID:17244360.
   PubMed Web of Science ®Google Scholar
• Whitehurst AW. Cause and consequence of cancer/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol 2014;54:251–272. PubMed PMID:24160706.
   PubMed Web of Science ®Google Scholar
• Lim SH, Zhang Y, Zhang J. Cancer-testis antigens: the current status on antigen regulation and potential clinical use. Am J Blood Res 2012;2(1):29–35. PubMed PMID:22432085.
   PubMedGoogle Scholar
• Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009;100(11):2014–2021. PubMed PMID:19719775.
   PubMed Web of Science ®Google Scholar
• Escors D. Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J Sci 2014:25 pages. PubMed PMID:24634791.
   Google Scholar
• Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5(8):615–625. PubMed PMID:16034368.
   PubMed Web of Science ®Google Scholar
• Serrano A, Tanzarella S, Lionello I, et al. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2’-deoxycytidine treatment. Int J Cancer 2001;94(2):243–251. PubMed PMID:11668505.
   Google Scholar
• Graff-Dubois S, Faure O, Gross DA, et al. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol 2002;169(1):575–580. PubMed PMID: 12077290.
   Google Scholar
• Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009;10(5):371–374. PubMed PMID: 19808198.
   PubMed Web of Science ®Google Scholar
• Goodyear O, Agathanggelou A, Novitzky-Basso I, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010;116(11):1908–1918. PubMed PMID:20530795.
   PubMed Web of Science ®Google Scholar
• Cruz CR, Gerdemann U, Leen AM, et al. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res 2011;17(22):7058–7066. PubMed PMID:21908573.
   PubMed Web of Science ®Google Scholar
• Sang M, Wang L, Ding C, et al. Melanoma-associated antigen genes –an update. Cancer Lett 2011;302(2):85–90. PubMed PMID:21093980.
   Google Scholar
• Curigliano G, Spitaleri G, Pietri E, et al. Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol 2006;17(5):750–762. PubMed PMID:16293674.
   Google Scholar
• Zhou J, Zhong Y. Breast cancer immunotherapy. Cell Mol Immunol 2004;1(4):247–255. PubMed PMID:16225767.
   PubMed Web of Science ®Google Scholar
• Chapuis AG, Thompson JA, Margolin KAet al., Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci USA 2012;109(12):4592–4597. PubMed PMID:22393002.
   PubMed Web of Science ®Google Scholar
• Le HK, Graham L, Miller CH, et al. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. Cancer Immunol Immunother 2009;58(10):1565–1576. PubMed PMID:19198835.
   Google Scholar
• Hoon DS, Kitago M, Kim J, et al. Molecular mechanisms of metastasis. Cancer Metastasis Rev 2006;25(2):203–220. PubMed PMID:16770533.
   Google Scholar
• Gurchot C. The trophoblast theory of cancer (John Beard, 1857–1924) revisited. Oncology 1975;31(5–6):310–333. PubMed PMID:1107920.
   Google Scholar
• Burleigh AR. Of germ cells, trophoblasts, and cancer stem cells. Integr Cancer Ther 2008;7(4):276–281. PubMed PMID:19116223.
   Google Scholar
• Acevedo HF, Tong JY, Hartsock RJ. Human chorionic gonadotropin-beta subunit gene expression in cultured human fetal and cancer cells of different types and origins. Cancer 1995;76(8):1467–1475. PubMed PMID:8620425.
   Google Scholar
• Chen YT, Scanlan MJ, Venditti CA, et al. Identification of cancer/testis-antigen genes by massively parallel signature sequencing. Proc Natl Acad Sci USA 2005;102(22):7940–7945. PubMed PMID:15905330.
   Google Scholar
• Grizzi F, Chiriva-Internati M, Franceschini B, et al. Immunolocalization of sperm protein 17 in human testis and ejaculated spermatozoa. J Histochem Cytochem 2003;51(9):1245–1248. PubMed PMID:12923251.
   Google Scholar
• Grizzi F, Chiriva-Internati M, Franceschini B, et al. Sperm protein 17 is expressed in human somatic ciliated epithelia. J Histochem Cytochem 2004;52(4):549–554. PubMed PMID:15034007.
   Google Scholar
• Lim SH, Wang Z, Chiriva-Internati M, Xue Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 2001;97(5):1508–1510. PubMed PMID:11222401.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Wang Z, Salati E, et al. Tumor vaccine for ovarian carcinoma targeting sperm protein 17. Cancer 2002;94(9):2447–2453. PubMed PMID:12015770.
   PubMedGoogle Scholar
• Gupta G, Sharma R, Chattopadhyay TK, et al. Clinical significance of sperm protein 17 expression and immunogenicity in esophageal cancer. Int J Cancer 2007;120(8):1739–1747. PubMed PMID:17230514.
   Google Scholar
• Bumm K, Grizzi F, Franceschini B, et al. Sperm protein 17 expression defines 2 subsets of primary esthesioneuroblastoma. Hum Pathol 2005;36(12):1289–1293. PubMed PMID:16311122.
   Google Scholar
• Grizzi F, Gaetani P, Franceschini B, et al. Sperm protein 17 is expressed in human nervous system tumours. BMC Cancer 2006;6:23. PubMed PMID:16438728.
   PubMedGoogle Scholar
• Nelson PT, Zhang PJ, Spagnoli GC, et al. Cancer/testis (CT) antigens are expressed in fetal ovary. Cancer Immun 2007;7:1. PubMed PMID:17217256.
   PubMedGoogle Scholar
• Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5(8):615–625. PubMed PMID:16034368.
   PubMed Web of Science ®Google Scholar
• Old LJ. Cancer/testis (CT) antigens –a new link between gametogenesis and cancer. Cancer Immun 2001;1:1. PubMed PMID:12747762.
   PubMedGoogle Scholar
• Jager E, Knuth A. The discovery of cancer/testis antigens by autologous typing with T cell clones and the evolution of cancer vaccines. Cancer Immun 2012;12:6. PubMed PMID:22896751.
   Google Scholar
• van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254(5038):1643–1647. PubMed PMID:1840703.
   PubMed Web of Science ®Google Scholar
• Chen YT, Gure AO, Tsang S, et al. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 1998;95(12):6919–6923. PubMed PMID:9618514.
   PubMed Web of Science ®Google Scholar
• Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94(5):1914–1918. PubMed PMID:9050879.
   PubMed Web of Science ®Google Scholar
• Li G, Miles A, Line A, Rees RC. Identification of tumour antigens by serological analysis of cDNA expression cloning. Cancer Immunol Immunother 2004;53(3):139–143. PubMed PMID:14722670.
   PubMed Web of Science ®Google Scholar
• Pagotto A, Caballero OL, Volkmar N, et al. Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells. PloS One 2013;8(12):e83212. PubMed PMID:24340093.
   PubMed Web of Science ®Google Scholar
• Almeida LG, Sakabe NJ, deOliveira AR, et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 2009;37(Database issue):D816–D819. PubMed PMID:18838390.
   Google Scholar
• Chen YT, Venditti CA, Theiler G, et al. Identification of CT46/HORMAD1, an immunogenic cancer/testis antigen encoding a putative meiosis-related protein. Cancer Immun 2005;5:9. PubMed PMID:15999985.
   PubMedGoogle Scholar
• Ono T, Kurashige T, Harada Net al., Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc Natl Acad Sci USA 2001;98(6):3282–3287. PubMed PMID:11248070.
   PubMed Web of Science ®Google Scholar
• Tureci O, Sahin U, Zwick Cet al., Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci USA 1998;95(9):5211–5216. PubMed PMID:9560255.
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004;4:1. PubMed PMID:14738373.
   PubMedGoogle Scholar
• Hofmann O, Caballero OL, Stevenson BJet al., Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci USA 2008;105(51):20422–20427. PubMed PMID:19088187.
   PubMed Web of Science ®Google Scholar
• Westbrook VA, Diekman AB, Klotz KL, et al. Spermatid-specific expression of the novel X-linked gene product SPAN-X localized to the nucleus of human spermatozoa. Biol Reprod 2000;63(2):469–481. PubMed PMID:10906052.
   Google Scholar
• Kouprina N, Noskov VN, Pavlicek A, et al. Evolutionary diversification of SPANX-N sperm protein gene structure and expression. PloS One 2007;2(4):e359. PubMed PMID:17406683.
   Google Scholar
• Laduron S, Deplus R, Zhou S, et al. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res 2004;32(14):4340–4350. PubMed PMID:15316101.
   PubMedGoogle Scholar
• Freitas M, Malheiros S, Stavale JN, et al. Expression of cancer/testis antigens is correlated with improved survival in glioblastoma. Oncotarget 2013;4(4):636–646. PubMed PMID:23592437.
   PubMed Web of Science ®Google Scholar
• Syed ON, Mandigo CE, Killory BD, et al. Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma. J Clin Neurosci 2012;19(7):1016–1021. PubMed PMID:22534618.
   PubMed Web of Science ®Google Scholar
• Oba-Shinjo SM, Caballero OL, Jungbluth AA, et al. Cancer-testis (CT) antigen expression in medulloblastoma. Cancer Immun 2008;8:7. PubMed PMID:18426187.
   PubMedGoogle Scholar
• Okuyama R, Aruga A, Hatori T, et al. Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. Oncoimmunology 2013;2(11):e27010. PubMed PMID:24498547.
   Web of Science ®Google Scholar
• Cogdill AP, Frederick DT, Cooper ZA, et al. Targeting the MAGE A3 antigen in pancreatic cancer. Surgery 2012;152(3 Suppl 1):S13–S18. PubMed PMID:22770803.
   PubMed Web of Science ®Google Scholar
• Wadle A, Kubuschok B, Imig J, et al. Serological immune response to cancer testis antigens in patients with pancreatic cancer. Int J Cancer 2006;119(1):117–125. PubMed PMID:16432832.
   PubMed Web of Science ®Google Scholar
• Schmitz-Winnenthal FH, Galindo-Escobedo LV, Rimoldi D, et al. Potential target antigens for immunotherapy in human pancreatic cancer. Cancer Lett 2007;252(2):290–298. PubMed PMID:17320278.
   Google Scholar
• Fox BA, Schendel DJ, Butterfield LH, et al. Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011;9(1):214. PubMed PMID:22168571.
   PubMedGoogle Scholar
• Doyle JM, Gao J, Wang J, et al. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol Cell 2010;39(6):963–974. PubMed PMID:20864041.
   PubMed Web of Science ®Google Scholar
• Grizzi F, Chiriva-Internati M. The complexity of anatomical systems. Theor Biol Med Mod 2005;2:26. PubMed PMID:16029490.
   PubMed Web of Science ®Google Scholar
• Grizzi F, Chiriva-Internati M. Cancer: looking for simplicity and finding complexity. Cancer Cell Int 2006;6:4. PubMed PMID:16480511.
   PubMed Web of Science ®Google Scholar
• Bizzarri M, Giuliani A, Cucina A, et al. Fractal analysis in a systems biology approach to cancer. Semin Cancer Biol 2011;21(3):175–182. PubMed PMID:21514387.
   PubMed Web of Science ®Google Scholar
• Powathil GG, Swat M, Chaplain MAJ. Systems oncology: towards patient-specific treatment regimes informed by multiscale mathematical modelling. Semin Cancer Biol 2015;30:13–20. PubMed PMID:24607841.
   Google Scholar
• Byrne HM. Dissecting cancer through mathematics: from the cell to the animal model. Nat Rev Cancer 2010;10(3):221–230. PubMed PMID:20179714.
   PubMed Web of Science ®Google Scholar
• Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Ann Rev Pathol 2013;8:277–302. PubMed PMID:23092187.
   PubMed Web of Science ®Google Scholar
• Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012;72(19):4875–4882. PubMed PMID:23002210.
   PubMed Web of Science ®Google Scholar
• Janku F. Tumor heterogeneity in the clinic: is it a real problem? Ther Adv Med Oncol 2014;6(2):43–51. PubMed PMID:24587830.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Grizzi F, Bright RK, Martin Kast W. Cancer immunotherapy: avoiding the road to perdition. J Transl Med 2004;2(1):26. PubMed PMID:15283862.
   Google Scholar
• Bouchlaka MN, Murphy WJ. Impact of aging in cancer immunotherapy: the importance of using accurate preclinical models. Oncoimmunology 2013;2(12):e27186. PubMed PMID:24498569.
   Google Scholar
• Mao Y, Poschke I, Kiessling R. Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells. J Int Med 2014;276(2);154–170. PubMed PMID:24597954.
   Google Scholar
• Bouchlaka MN, Sckisel GD, Chen M, et al. Aging predisposes to acute inflammatory-induced pathology after tumor immunotherapy. J Exp Med 2013;210(11):2223–2237.
   PubMed Web of Science ®Google Scholar